Sort
3,198 grants matching “mrna vaccine”
Advancement of poxvirus inhibitor
$656,410John H Connor · Boston University Medical Campus · R01 · FY2023 · AI
IMMUNE REGULATION AND VACCINE DEVELOPMENT IN LEISHMANIASIS
$655,874David Sacks · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
Lung immune function in human TB infection and its perturbation by HIV-1.
$653,018David G Russell · Cornell University · R01 · FY2024 · AI
Developing antiviral agents that inhibit HCV translation
$652,409Ptc Therapeutics, Inc. · R44 · FY2004 · AI
Developing antiviral agents that inhibit HCV translation
$652,409Ptc Therapeutics, Inc. · R44 · FY2005 · AI
COVID-19 vaccine development research
$650,195Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
MEPCS (Multi-epitope protease cleavage sites) vaccine for protecting against SIV rectal transmission
$650,156Qingsheng Li · University Of Nebraska Lincoln · R01 · FY2024 · AI
CAREER: Developing albumin-binding responsive polypeptides for nucleic acid delivery
$650,000Fuwu Zhang · University Of Miami · · FY2023 · MPS
INFLUENZA A VIRUSES (IAV) CAUSE SIGINIFIANCT ECOMONIC LOSS IN LIVESTOCK INDUSTRY. THE ZOONOTIC NATURE OF THE VIRUS ALSO POSE A SIGNIFICANT PANDEMIC THREAT TO HUMAN POPULATION. PIGS HAVE LONG BEEN CONSIDERED A MIXING VESSEL FOR GENERATION OF NOVEL INFLUENZA VIRUSES. THE RECENT EMERGENCE AND OUTBREAKS OF HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI) H5N1 VIRUS IN CATTLE HAVE INCREASED CONCERN OF IAV PANZOOTIC/PANDEMIC IN ANIMALS AND HUMAN POPULATION. AN UNIVERSAL VACCINE THAT CAN INDUCE STRONG, BROADLY PROTECTIVE IMMUNITY AGAINST GENETICALLY DIVERSIFIED VIRAL STRAINS IS URGENTLY NEEDED. CURRENT COMMERCIAL INFLUENZA VACCINE PLATFORMS AND MANUFACTURING PROCEDURES PRESENT A CHALLENGE FOR US TO RESPOND TO AN INFLUENZA OUTBREAK IN A TIMELY MANNER. NUCLEIC ACID-BASED (MRNA) VACCINE PLATFORMS ALLOW FOR FLEXIBLE, NIMBLE, LARGE-SCALE PRODUCTION OF VACCINES, WHICH CAN MEET THE RAPID MANUFACTURING REQUIREMENTS DURING AN INFLUENZA OUTBREAK. IN THIS PROPOSED STUDY, WE WILL TEST AN MRNA VACCINE COCKTAIL, WHICH CONTAINS A MIXTURE OF MRNAS ENCODING A CHIMERIC HA (H1) GLOBULAR HEAD, WITH TWO TYPES OF CONSERVED HA STALK DOMAIN COVERING 16 IAV SUBTYPES, AND THE H5 ANTIGEN FROM HPAI H5N1. THESE MRNAS WILL BE DELIVERED BY A NOVEL CLASS OF PEPTIDE-BASED CATIONIC NANOPARTICLES (PNP) FEATURING RESISTANCE TO OXIDATION AND THERMAL STABILITY. THIS CANDIDATE MRNA-PNP VACCINE WILL BE INITIALLY CHARACTERIZED IN CELL CULTURE MODEL AND THE IMMUNOGENICITY OF VACCINE WILL BE ASSESSED IN ANIMAL MODELS, INCLUDING PIGS AND CALVES.
$649,896University Of Illinois · · FY2025 · National Institute of Food and Agriculture
THE INFLUENZA VIRUS HAS BEEN RESPONSIBLE FOR SEVERAL PANDEMICS, AND HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI) VIRUSES REMAIN A SIGNIFICANT THREAT TO PUBLIC HEALTH. A RECENT SPILLOVER OF THE HPAI H5N1 VIRUS TO DAIRY COWS HAS LED TO HUMAN INFECTIONS, HIGHLIGHTING THE NEED FOR SAFE AND EFFECTIVE VACCINES TO PREVENT INFLUENZA AIRWAY INFECTIONS IN COWS AND REDUCE SPREAD BETWEEN ANIMALS AND HUMANS. CURRENT INTRAMUSCULAR VACCINES, SUCH AS MRNA VACCINES, ARE HIGHLY EFFECTIVE IN REDUCING SEVERE DISEASES AND DEATHS BUT DO NOT PREVENT RESPIRATORY INFECTIONS AND TRANSMISSION. THIS LIMITATION ARISES BECAUSE INTRAMUSCULAR VACCINES PRIMARILY STIMULATE SYSTEMIC IMMUNITY, WHICH IS INSUFFICIENT FOR PROTECTING THE RESPIRATORY MUCOSA. TO ADDRESS THIS CHALLENGE, DEVELOPING MUCOSAL VACCINES THAT ELICIT LONG-LASTING MUCOSAL IMMUNITY IS ESSENTIAL. THESE VACCINES COULD PREVENT BOTH INITIAL AND RECURRENT INFLUENZA VIRUS INFECTIONS AND THEIR TRANSMISSION. RECENT STUDIES HAVE DEMONSTRATED THAT USING AN FCRN-BASED PLATFORM TO DELIVER INFLUENZA HEMAGGLUTININ (HA) AND SARS-COV-2 SPIKE ANTIGENS THROUGH THE AIRWAY CAN INDUCE PROTECTIVE MUCOSAL IMMUNITY IN BOTH THE NASAL AND LUNG COMPARTMENTS. THIS NASAL VACCINE EFFECTIVELY PREVENTS VIRUS REPLICATION IN ANIMALS AND LIMITS TRANSMISSION AMONG THEM. THESE FINDINGS LED US TO REASON THAT FCRN-MEDIATED NASAL SPRAY VACCINES FOR INFLUENZA CAN TRIGGER RECALL RESPONSES THAT PROTECT AGAINST INITIAL AND RECURRENT H5N1 INFECTIONS IN THE AIRWAY AND REDUCE ANIMAL-TO-ANIMAL AND ANIMAL-TO-HUMAN TRANSMISSION. GIVEN THE RAPIDLY EVOLVING NATURE OF INFLUENZA VIRUSES, WE AIM TO DEVELOP UNIVERSAL MUCOSAL VACCINES. THE VACCINES DELIVERED THROUGH THE FCRN PLATFORM CAN BE EASILY ENGINEERED, MANUFACTURED, AND ADAPTED FOR USE AGAINST OTHER MUCOSAL INFECTIONS IN LIVESTOCK.
$648,881University Of Maryland, College Park · · FY2025 · National Institute of Food and Agriculture
Software for the complete characterization of antibody repertoires: from germline and mRNA sequence assembly to deep learning predictions of their protein structures and targets
$648,790Timothy J Durfee · Dnastar, Inc. · R44 · FY2023 · GM
Immunity to Pneumonic Tularemia
$647,802Catharine Bosio · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Develop lung-targeted synthetic lipid nanoparticles for mRNA medicine treating pulmonary lymphangioleiomyomatosis
$645,566Qiaobing Xu · Tufts University Medford · R01 · FY2025 · HL
A phase I study of RNA-lipid particle vaccines for newly-diagnosed glioblastoma, IND19304 08/21/2020
$645,379Elias Sayour · University Of Florida · R01 · FY2025 · FD
Profiling the Leishmania-macrophage Host-pathogen Infectome
$644,663Najib M. El-Sayed · Univ Of Maryland, College Park · R01 · FY2012 · AI
Systemic RNA Delivery to Tumors
$644,550Jinjun Shi · Brigham And Women'S Hospital · R01 · FY2016 · CA
Replication of influenza virus
$642,396Robert M Krug · University Of Texas At Austin · R01 · FY2008 · AI
Host Immune Responses to Antigens of Malaria Parasites
$641,821Carole Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Development of Universal Influenza Virus Vaccines Using Nucleoside-Modified Messenger RNA
$640,818Norbert Pardi · University Of Pennsylvania · R01 · FY2019 · AI
Poxvirus Gene Expression
$640,709Bernard Moss · National Institute Of Allergy And Infectious Diseases · ZIA · FY2013 · AI
Targeting Immunosuppression Pathways to Enhance Brain Tumor Immunotherapy
$640,259John H Sampson · Duke University · P01 · FY2015 · CA
Strategies for Cancer Vaccine Development: Preclinical Studies
$639,402Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Cancer Immune-Interception for Lynch Syndrome
$639,370Eduardo Vilar Sanchez · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Targeting Immunosuppression Pathways to Enhance Brain Tumor Immunotherapy
$639,245John H Sampson · Duke University · P01 · FY2016 · CA
Poxvirus Gene Expression and DNA Replication
$638,961Bernard Moss · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI